ICMR Issues New Guidelines for Type 1 Diabetes Management

The Indian Council of Medical Research (ICMR) has issued comprehensive guidelines for the management of Type 1 Diabetes Mellitus (T1DM), a chronic autoimmune condition characterized by the destruction of insulin-producing beta cells in the pancreas. These guidelines are crucial for healthcare providers in India, where the diabetes burden is significant. This blog delves into the specifics of the ICMR guidelines, providing a detailed yet accessible overview.

Type 1 Diabetes Mellitus (T1DM) affects approximately 1.1 million people under the age of 20 globally, with 0.13 million new cases diagnosed annually. India, notably, has the highest number of incidents and prevalent cases of T1DM worldwide. The ICMR guidelines provide a structured approach to managing this chronic condition, emphasizing the need for meticulous blood glucose monitoring, insulin administration, lifestyle modifications, and regular screening for complications.

Epidemiology and Diagnosis


The ICMR highlights that T1DM is most commonly diagnosed in individuals between 10-14 years of age, though it can present at any age. In India, the prevalence of T1DM is approximately 3.9 per 100,000 children aged 0-14 years, with an annual incidence rate of 4.2 per 100,000 children.


The diagnosis of T1DM is based on clinical presentation and specific laboratory tests. The ICMR recommends the following diagnostic criteria:

  • Fasting Plasma Glucose (FPG): ≥126 mg/dL
  • Oral Glucose Tolerance Test (OGTT): 2-hour plasma glucose ≥200 mg/dL
  • Glycated Hemoglobin (HbA1c): ≥6.5%
  • Random Plasma Glucose: ≥200 mg/dL in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis

These cut-offs are aligned with the American Diabetes Association (ADA) recommendations and are crucial for confirming the diagnosis of T1DM.

Pathogenesis and Natural History

T1DM is primarily an autoimmune condition with significant genetic predisposition. The ICMR notes that genetic markers such as HLA DR3-DQ2 and DR4-DQ8 are associated with increased risk. Environmental factors, including viral infections and early life weight gain, also contribute to the disease’s pathogenesis.

The natural history of T1DM, as outlined by the ICMR, progresses through several stages:

  1. Stage 1 (Pre-symptomatic): Presence of beta-cell autoimmunity with normoglycemia.
  2. Stage 2 (Pre-symptomatic): Beta-cell autoimmunity with dysglycemia.
  3. Stage 3: Onset of symptomatic disease.

Lifestyle Management: Diet and Exercise

The ICMR emphasizes that lifestyle modifications, particularly diet and exercise, are integral to managing T1DM effectively.


A balanced diet tailored to individual needs is crucial. Key dietary recommendations by the ICMR include:

  • Regular Meals and Snacks: To maintain consistent blood glucose levels.
  • Carbohydrate Counting: To adjust insulin doses accurately.
  • Fiber-rich Foods and Healthy Fats: To improve overall nutrition.
  • Limiting Simple Sugars and Refined Carbohydrates: To prevent spikes in blood glucose levels.


Regular physical activity is essential for improving insulin sensitivity and overall well-being. The ICMR recommends:

  • 150 Minutes of Moderate Aerobic Exercise per Week: Such as walking, cycling, or swimming.
  • Strength Training Exercises at Least Twice a Week: To build muscle and improve metabolism.
  • Monitoring Blood Glucose Levels: Before, during, and after exercise to prevent hypoglycemia.

Pharmacological Management: Insulin and Other Medications

Pharmacological Management: Insulin and Other Medications

Insulin Therapy

Insulin is the cornerstone of T1DM management. According to the ICMR, the types of insulin include:

  • Rapid-acting Insulin
  • Short-acting Insulin
  • Intermediate-acting Insulin
  • Long-acting Insulin

The ICMR recommends intensive insulin therapy, which mimics natural insulin release, including:

  • Multiple Daily Injections (MDI): Combining basal and bolus insulin.
  • Continuous Subcutaneous Insulin Infusion (CSII): Using an insulin pump for continuous delivery.

Other Medications

While insulin remains the primary treatment, the ICMR acknowledges the use of other medications to manage associated conditions like hypertension and dyslipidemia, which are common in T1DM patients.

Monitoring Metabolic Control

Regular monitoring of blood glucose levels is vital for managing T1DM. The ICMR recommends:

  • Self-Monitoring of Blood Glucose (SMBG): Using glucometers to check blood sugar levels multiple times a day.
  • Continuous Glucose Monitoring (CGM): For real-time tracking of glucose levels.
  • Periodic HbA1c Testing: Every 3-6 months to assess long-term glycemic control.

Management of Acute Complications

Diabetic Ketoacidosis (DKA)

DKA is a life-threatening complication characterized by hyperglycemia, ketosis, and acidosis. The ICMR outlines a management protocol that includes:

  • Intravenous Insulin: To reduce blood glucose levels.
  • Fluid and Electrolyte Replacement: To correct dehydration and electrolyte imbalances.
  • Monitoring and Correcting Acid-Base Balance: To address metabolic acidosis.


Hypoglycemia, or low blood glucose levels, can occur due to excessive insulin, missed meals, or strenuous exercise. The ICMR recommends:

  • Immediate Intake of Fast-acting Carbohydrates: Such as glucose tablets or fruit juice.
  • Adjusting Insulin Doses and Meal Plans: To prevent future episodes.

Management of Chronic Complications

Microvascular Complications

  • Retinopathy: The ICMR recommends annual eye exams and controlling blood glucose and blood pressure to prevent diabetic retinopathy.
  • Nephropathy: Annual screening for albuminuria and maintaining optimal blood glucose and blood pressure levels are essential to prevent kidney damage.

Advanced Care and Technology Integration

Continuous Glucose Monitoring (CGM) and Insulin Pumps

The ICMR recognizes the role of advanced technologies like Continuous Glucose Monitoring (CGM) systems and insulin pumps in enhancing diabetes management. These devices provide real-time data, enabling more precise insulin dosing and better glycemic control.

  • CGM Systems: These devices measure interstitial glucose levels every few minutes, providing detailed glucose trends. The ICMR guidelines advocate for the use of CGM systems, particularly in children and adolescents, to reduce hypoglycemia and improve HbA1c levels.
  • Insulin Pumps: Also known as Continuous Subcutaneous Insulin Infusion (CSII) devices, insulin pumps deliver a steady flow of insulin and allow for bolus doses around mealtimes. The ICMR recommends insulin pump therapy for patients who struggle with multiple daily injections or who need tighter glycemic control.

Artificial Pancreas Systems

An emerging technology, the artificial pancreas system, combines CGM and insulin pump technologies with advanced algorithms to automate insulin delivery. While still in the developmental and early adoption stages, the ICMR highlights the potential of these systems to significantly improve T1DM management outcomes by reducing the burden on patients and optimizing glucose control.

Psychological and Social Support

Living with T1DM can be psychologically taxing, and the ICMR emphasizes the importance of comprehensive support systems.

Psychological Counseling

The ICMR recommends regular psychological counseling to help patients and their families cope with the emotional and psychological challenges of T1DM. Counseling can address issues such as anxiety, depression, and diabetes-related distress.

Support Groups

Support groups provide a platform for individuals with T1DM to share experiences, challenges, and strategies for managing their condition. The ICMR encourages the formation of local support groups and participation in diabetes associations to foster a sense of community and support.

Research and Future Directions

Ongoing Research

The ICMR underscores the importance of ongoing research to improve T1DM management. Areas of focus include:

  • Beta-cell Replacement Therapies: Research into islet cell transplantation and stem cell therapies aims to restore endogenous insulin production.
  • Immunotherapy: Developing therapies to halt or reverse the autoimmune process that destroys beta cells.
  • Artificial Pancreas Systems: Enhancing the algorithms and integrating more robust safety features to improve the efficacy and adoption of artificial pancreas systems.

Emerging Treatments

The ICMR is closely monitoring the development of emerging treatments, such as SGLT2 inhibitors and GLP-1 receptor agonists, which may offer additional benefits in managing T1DM. These therapies, primarily used in Type 2 diabetes, are being studied for their potential to improve glycemic control and reduce cardiovascular risks in T1DM patients.

Policy Recommendations

The ICMR makes several policy recommendations to ensure that the management of T1DM is effective and accessible:

Access to Medications and Supplies

The ICMR advocates for policies that ensure affordable and reliable access to insulin, glucose monitoring devices, and other essential supplies. Government programs and subsidies can play a crucial role in making these resources accessible to all patients.

Training and Education for Healthcare Providers

Ongoing education and training for healthcare providers are essential to ensure they are up-to-date with the latest management strategies and technologies. The ICMR recommends regular workshops, seminars, and certification programs for endocrinologists, diabetologists, and primary care physicians.

Public Awareness Campaigns

Raising public awareness about T1DM, its symptoms, and the importance of early diagnosis and management is critical. The ICMR suggests implementing nationwide campaigns to educate the public and reduce the stigma associated with diabetes.


The ICMR guidelines for the management of Type 1 Diabetes Mellitus provide a comprehensive, evidence-based framework that addresses all aspects of care. From diagnosis and lifestyle management to advanced technologies and psychological support, these guidelines aim to improve the quality of life for individuals with T1DM.

By adhering to these guidelines, healthcare providers can offer more effective, personalized care, ultimately reducing the burden of diabetes in India. As research continues to advance, the ICMR remains committed to updating and refining these guidelines to incorporate new findings and technologies, ensuring that patients receive the best possible care.


The ICMR guidelines offer detailed recommendations for managing T1DM, emphasizing the importance of:

  • Early and accurate diagnosis using specific clinical and laboratory criteria.
  • Comprehensive lifestyle management, including tailored diet and regular exercise.
  • Intensive insulin therapy through MDI or CSII.
  • Regular monitoring of blood glucose and HbA1c levels.
  • Effective management of acute and chronic complications.
  • Specialized care during pregnancy, travel, and surgery.
  • Integration of advanced technologies like CGM systems and insulin pumps.
  • Psychological and social support for patients and their families.
  • Ongoing research and the adoption of emerging treatments.

By following these guidelines, healthcare providers can significantly improve the outcomes and quality of life for individuals with T1DM, addressing both the clinical and psychosocial aspects of this complex condition. The ICMR’s commitment to continuous improvement and adaptation of these guidelines ensures that they remain relevant and effective in the face of evolving challenges and technological advancements.Last Updated on by Dr. Damanjit Duggal 


This site provides educational content; however, it is not a substitute for professional medical guidance. Readers should consult their healthcare professional for personalised guidance. We work hard to provide accurate and helpful information. Your well-being is important to us, and we value your feedback. To learn more, visit our editorial policy page for details on our content guidelines and the content creation process.

Leave a Reply


Download Free Diabetes Diet Plan

Download Diet Plan